On June 8, 2016, Sabinsa filed suit against Aegle for willful infringement of the curcumin Patent No. 6,653,327, which protects Sabinsa’s methods and formulations for tetrahydrocurcuminoids (THCs).
The judgement stipulates that the patent was valid, enforceable, and properly issued by the US Patent and Trademark Office.
Sabinsa has patents related to THCs in the United States, Europe, Australia, New Zealand, and other locations.
In the US, Sabinsa continues to litigate the amount owed for willful infringement of the ’327 patent by Olive Lifesciences Private Limited after obtaining final judgments against Chemill Inc. and Nachurel Ingredients.
“As a pioneer in the industry, Sabinsa has researched and developed many innovative and successful products used by the nutritional supplement industry, but unfortunately that success has made us a target for IP theft,” said Sabinsa founder Dr. Muhammed Majeed. “Out of necessity, Sabinsa has earned a reputation for strong enforcement of our intellectual property rights, and will continue to pursue all available legal remedies to protect those rights when necessary.”